Table 2

Results: P. aeruginosa clinical and microbiologic success, baseline and emergent resistance rates*

First author, year

Study arm

PA isolates (n)

Clinical success (%)

Microbiologic eradication (%)

Resistance at baseline (%)

Emergent resistance (%)


Chastre, 2008 [39]

Imipenem

25

42.9

35.7

24.0

52.6

Comparator

28

80.0

65.0

0.0

35.7

Yanagihara, 2005 [40]

Imipenem

4

50.0

Comparator

3

0.0

Joshi, 2006 [42]

Imipenem

17

70.6

Comparator

18

76.5

Romanelli, 2006 [43]

Imipenem

1

0.0

0.0

Comparator

1

0.0

0.0

Shorr, 2005 [44]

Imipenem

18

72.0

5.6

Comparator

16

85.0

6.3

Zanetti, 2003 [45]

Imipenem

32

15.6

28.1

Comparator

27

7.4

11.1

West, 2003 [46]

Imipenem

17

41.2

29.4

Comparator

17

64.7

58.8

Torres, 2000 [47]

Imipenem

12

66.0

25.0

33.0

Comparator

14

71.0

50.0

7.0

Bartoloni, 1999 [48]

Imipenem

3

66.6

66.7

Comparator

1

100.0

100.0

Jaccard, 1998 [49]

Imipenem

24

50.0

4.2

25.0

Comparator

21

90.5

0.0

4.8

Ho, 1997 [51]

Imipenem

2

50.0

Comparator

3

100.0

Raad, 1996 [52]

Imipenem

1

0.0

Comparator

4

75.0

Vic, 1996 [53]

Imipenem

1

100.0

Comparator

19

100.0

Bohme, 1995 [54]

Imipenem

3

66.0

66.0

Comparator

0

NA

NA

Siami, 1995 [55]

Imipenem

9

77.8

Comparator

12

41.7

Cometta, 1994 [56]

Imipenem

24

55.6

33.3

Comparator

23

50.0

56.5

Fink, 1994 [57]

Imipenem

44

25.0

50.0

Comparator

47

27.7

28.0

Norrby, 1993 [58]

Imipenem

14

42.1

42.9

Comparator

16

82.4

6.3

Pooled rates

Imipenem

251

45.2

47.6

14.6

38.7

Comparator

270

74.9

52.8

2.5

21.9


*Limited to studies reporting at least one of these outcomes; empty cells indicate that the corresponding data were not reported

Although the total pseudomonal isolates in the two arms of each analysis add up to the same number (n = 34), the distribution between the arms is different presumably due to reclassification of a single PA isolate from the levofloxacin to the imipenem arm, which occurred between the West [46] publication and the Shorr [44] analysis.

PA:Pseudomonas aeruginosa; NA: not applicable

Zilberberg et al. BMC Pulmonary Medicine 2010 10:45   doi:10.1186/1471-2466-10-45

Open Data